Table 3.
Vaccine under various phases: II/III, and III (as of January 2021).
| Phase | Name | Developer | Type | Design, Product Description | Efficacy | Country | Status |
|---|---|---|---|---|---|---|---|
| Phase 2/3 | Comirnaty | Pfizer/BioNTech | mRNA | Muscle Injection/Freezer storage (−70C), 2 doses, 3 weeks apart | 95% | USA | Approved in several countries, emergenecy in USA, elsewhere |
| Phase 3 | mRNA-1273 | Moderna | mRNA | Muscle Injection/30 days with refrigeration, 6 months at −20C, 2 doses, 4 weeks apart | 94.50% | USA | Approved in canada, emergency use in U.S., E.U., Israel |
| Phase 3 | Sputnik V | Gamaleya | Ad5 and AD26 | Muscle injection, Freezer storage. Developing an alternative formulation that can be refrigerated, 2 doses, 3 weeks apart | 91.40% | Russia | Early use in Russia, elsewhere |
| Phase 2/3 | AZD1222 | Oxford/AstraZeneca | ChAdOx1 | Muscle injection, Stable in refrigerator for at least 6 months, 2 doses, 4 weeks apart | 62%–90% (depending on the dosage) | UK/Sweden | Emergency use in Britain, India, other countries. |
| Phase 3 | Convidecia | CanSinoBIO | Ad5 | Muscle injection, refrigerated, single dose | Unknown | China | Limited use in China |
| Phase 3 | EpiVacCorona | BEKTOP | Protein | Muscle injection, Stable in refrigerator for upto 2 years, 2 doses, 3 weeks apart | Unknown | Russia | Early use in Russia |
| Phase 3 | BBIBP-CorV | SINOPHARM | Inactivated | Muscle injection, 2 doses, 3 weeks apart | 79.34% | China | Approved in China, elsewhere |
| Phase 3 | CoronaVac | Sinovac | Inactivated | Muscle injection, 2 doses, Refrigerated, 2 weeks apart | 78% | China | Limited use in China |
| Phase 3 | Covaxin | Bharat BIOTECH | Inactivated | Atleast a week at room temperature, 2 doses, 4 weeks apart | unknown | india | Emergency use in India |
| Phase 3 | CVnCoV | CUREVAC | Inactivated | Muscle injection, Stable at 3 months at 2–8C, 2 doses, 4 weeks apart | unknown | USA | Under Trial |
| Phase 2/3 | AG0302-COVID1 | AnGes | Inactivated | Skin injection, over a year at room temperature, 2 doses, 2 weeks apart | unknown | japan | Under Trial |
| Phase 3 | ZyCoV-D | Zydus Cadila | Inactivated | Skin injection, stable at room temperature for three months, 3 doses, 4 weeks apart | unknown | India | Under Trial |
| Phase 3 | Ad26.COV2.S | Johnson-Johnson | Ad26 | Muscle injection, Upto 2 years at -4C, and upto 3 months refrigerated at 2–8C, 1 dose | unknown | USA/Israel | Under Trial |
| Phase 3 | NVX-CoV2373 | NOVAVAX | inactivated | Muscle injection, Stable in refrigerator, 2 doses, 3 weeks apart | unknown | USA | under Trial |
| Phase 3 | ZF2001 | Anhui Zhifei Longcom | inactivated | Muscle injection, 3 doses, 4 weeks apart | unknown | China | under Trial |
| Phase 3 | CoVLP | Medicago | inactivated | Muscle injection, Stable in refrigerator, 2 doses, 3 weeks apart | unknown | Canada | under Trial |